These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 30097504)

  • 1. Fibroblast-Activating Protein: Targeting the Roots of the Tumor Microenvironment.
    Siveke JT
    J Nucl Med; 2018 Sep; 59(9):1412-1414. PubMed ID: 30097504
    [No Abstract]   [Full Text] [Related]  

  • 2. Cancer-Targeting Functionalization of Selenium-Containing Ruthenium Conjugate with Tumor Microenvironment-Responsive Property to Enhance Theranostic Effects.
    Zhao Z; Gao P; You Y; Chen T
    Chemistry; 2018 Mar; 24(13):3289-3298. PubMed ID: 29288592
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A tumor multicomponent targeting chemoimmune drug delivery system for reprograming the tumor microenvironment and personalized cancer therapy.
    Sau S; Tatiparti K; Alsaab HO; Kashaw SK; Iyer AK
    Drug Discov Today; 2018 Jul; 23(7):1344-1356. PubMed ID: 29551455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor-associated macrophages, nanomedicine and imaging: the axis of success in the future of cancer immunotherapy.
    Zanganeh S; Spitler R; Hutter G; Ho JQ; Pauliah M; Mahmoudi M
    Immunotherapy; 2017 Sep; 9(10):819-835. PubMed ID: 28877626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanoparticles Targeting and Remodeling Tumor Microenvironment for Cancer Theranostics.
    Lin G; Chen S; Mi P
    J Biomed Nanotechnol; 2018 Jul; 14(7):1189-1207. PubMed ID: 29944095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Theranostic Probes for Targeting Tumor Microenvironment: An Overview.
    Sikkandhar MG; Nedumaran AM; Ravichandar R; Singh S; Santhakumar I; Goh ZC; Mishra S; Archunan G; Gulyás B; Padmanabhan P
    Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28492519
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Near-infrared-emitting heteroleptic cationic iridium complexes derived from 2,3-diphenylbenzo[g]quinoxaline as in vitro theranostic photodynamic therapy agents.
    Wang L; Yin H; Cui P; Hetu M; Wang C; Monro S; Schaller RD; Cameron CG; Liu B; Kilina S; McFarland SA; Sun W
    Dalton Trans; 2017 Jun; 46(25):8091-8103. PubMed ID: 28604869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted nanotechnologies for cancer intervention: a patent review (2010-2016).
    Pradeep P; Kumar P; Choonara YE; Pillay V
    Expert Opin Ther Pat; 2017 Sep; 27(9):1005-1019. PubMed ID: 28621571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunization of stromal cell targeting fibroblast activation protein providing immunotherapy to breast cancer mouse model.
    Meng M; Wang W; Yan J; Tan J; Liao L; Shi J; Wei C; Xie Y; Jin X; Yang L; Jin Q; Zhu H; Tan W; Yang F; Hou Z
    Tumour Biol; 2016 Aug; 37(8):10317-27. PubMed ID: 26842926
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Remodeling the Tumor Microenvironment with Emerging Nanotherapeutics.
    Chen Q; Liu G; Liu S; Su H; Wang Y; Li J; Luo C
    Trends Pharmacol Sci; 2018 Jan; 39(1):59-74. PubMed ID: 29153879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Theranostic 2D ultrathin MnO
    Liu Z; Zhang S; Lin H; Zhao M; Yao H; Zhang L; Peng W; Chen Y
    Biomaterials; 2018 Feb; 155():54-63. PubMed ID: 29169038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune Contexture, Immunoscore, and Malignant Cell Molecular Subgroups for Prognostic and Theranostic Classifications of Cancers.
    Becht E; Giraldo NA; Germain C; de Reyniès A; Laurent-Puig P; Zucman-Rossi J; Dieu-Nosjean MC; Sautès-Fridman C; Fridman WH
    Adv Immunol; 2016; 130():95-190. PubMed ID: 26923001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In Vivo Tumor Vasculature Targeting of CuS@MSN Based Theranostic Nanomedicine.
    Chen F; Hong H; Goel S; Graves SA; Orbay H; Ehlerding EB; Shi S; Theuer CP; Nickles RJ; Cai W
    ACS Nano; 2015; 9(4):3926-34. PubMed ID: 25843647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nanomedicines Targeting the Tumor Microenvironment.
    Tong R; Langer R
    Cancer J; 2015; 21(4):314-21. PubMed ID: 26222084
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peptide ligand-modified nanomedicines for targeting cells at the tumor microenvironment.
    David A
    Adv Drug Deliv Rev; 2017 Sep; 119():120-142. PubMed ID: 28506743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The fibroblast Tiam1-osteopontin pathway modulates breast cancer invasion and metastasis.
    Xu K; Tian X; Oh SY; Movassaghi M; Naber SP; Kuperwasser C; Buchsbaum RJ
    Breast Cancer Res; 2016 Jan; 18(1):14. PubMed ID: 26821678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor fibroblast specific activation of a hybrid ferritin nanocage-based optical probe for tumor microenvironment imaging.
    Ji T; Zhao Y; Wang J; Zheng X; Tian Y; Zhao Y; Nie G
    Small; 2013 Jul; 9(14):2427-31. PubMed ID: 23853124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting Tumor Microenvironment for Cancer Therapy.
    Roma-Rodrigues C; Mendes R; Baptista PV; Fernandes AR
    Int J Mol Sci; 2019 Feb; 20(4):. PubMed ID: 30781344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrated gene and miRNA expression analysis of prostate cancer associated fibroblasts supports a prominent role for interleukin-6 in fibroblast activation.
    Doldi V; Callari M; Giannoni E; D'Aiuto F; Maffezzini M; Valdagni R; Chiarugi P; Gandellini P; Zaffaroni N
    Oncotarget; 2015 Oct; 6(31):31441-60. PubMed ID: 26375444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hollow MnO
    Yang G; Xu L; Chao Y; Xu J; Sun X; Wu Y; Peng R; Liu Z
    Nat Commun; 2017 Oct; 8(1):902. PubMed ID: 29026068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.